OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Announce Fourth Quarter and Fiscal 2016 Financial Results on December 22

Download PDF

NEW YORK, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the fiscal year ended September 30, 2016 after the market close on Thursday, December 22, 2016.  The Company will also hold a live investor conference call and webcast at 5:00pm Eastern Time.

Conference Call & Webcast  
Thursday, December 22 at 5:00pm Eastern Time  
Domestic: 877-407-0789
International: 201-689-8562
Conference ID: 13651651
Webcast: http://public.viavid.com/index.php?id=122267
   
Replays – Available through December 29, 2016  
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 13651651

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being evaluated in combination with anti-VEGF injections in a Phase 3 clinical program for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform with several preclinical drug product candidates in development for glaucoma, steroid-induced glaucoma, ocular allergies, and protein drug delivery.  Additional information about the company may be found at www.ohrpharmaceutical.com.

Contact:
Ohr Pharmaceutical Inc. 
Investor Relations  
888-388-2327   
ir@ohrpharmaceutical.com 

LifeSci Advisors, LLC
Michael Wood
646-597-6983
mwood@lifesciadvisors.com

Primary Logo

Source: Ohr Pharmaceutical, Inc.